{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:18:59Z","timestamp":1792192739507,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2003,3,28]],"date-time":"2003-03-28T00:00:00Z","timestamp":1048809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1007\/s00280-002-0552-1","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T02:56:03Z","timestamp":1576119363000},"page":"311-320","source":"Crossref","is-referenced-by-count":69,"title":["High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL)"],"prefix":"10.1007","volume":"51","author":[{"given":"T.","family":"Sk\u00e4rby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hjorth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Behrentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bj\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Forestier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jarfelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"L\u00f6nnerholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,3,28]]},"reference":[{"key":"0552_CR1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1983.1.3.208","volume":"1","author":"Abelson","year":"1983","unstructured":"Abelson HT, Fosburg MT, Beardsley GP, Goorin AM, Gorka C, Link M, Link D (1983) Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1:208","journal-title":"J Clin Oncol"},{"key":"0552_CR2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3109\/00365518809088767","volume":"48","author":"Back","year":"1988","unstructured":"Back SE, Masson P, Nilsson Ehle P (1988) A simple chemical method for the quantification of the contrast agent iohexol, applicable to glomerular filtration rate measurements. Scand J Clin Lab Invest 48:825","journal-title":"Scand J Clin Lab Invest"},{"key":"0552_CR3","first-page":"110","volume":"35","author":"Bourke","year":"1975","unstructured":"Bourke RS, Chheda G, Bremer A, Watanabe O, Tower DB (1975) Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res 35:110","journal-title":"Cancer Res"},{"key":"0552_CR4","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/ndt\/13.5.1176","volume":"13","author":"Brandstrom","year":"1998","unstructured":"Brandstrom E, Grzegorczyk A, Jacobsson L, Friberg P, Lindahl A, Aurell M (1998) GFR measurement with iohexol and 51Cr-EDTA. A comparison of the two favoured GFR markers in Europe. Nephrol Dial Transplant 13:1176","journal-title":"Nephrol Dial Transplant"},{"key":"0552_CR5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.1988.6.5.797","volume":"6","author":"Christensen","year":"1988","unstructured":"Christensen ML, Rivera GK, Crom WR, Hancock ML, Evans WE (1988) Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia. J Clin Oncol 6:797","journal-title":"J Clin Oncol"},{"key":"0552_CR6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00558496","volume":"37","author":"Deray","year":"1989","unstructured":"Deray G, Khayat D, Cacoub P, Bourbouze R, Musset L, Baumelou A, Jacquillat C, Jacobs C (1989) The effects of diltiazem on methotrexate-induced nephrotoxicity. Eur J Clin Pharmacol 37:337","journal-title":"Eur J Clin Pharmacol"},{"key":"0552_CR7","first-page":"289","volume":"83","author":"Ferrari","year":"1992","unstructured":"Ferrari S, Orlandi M, Avella M, Caldora P, Ferraro A, Ravazzolo G, Bacci G (1992) Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate (in Italian). Minerva Med 83:289","journal-title":"Minerva Med"},{"key":"0552_CR8","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.1994.12.7.1443","volume":"12","author":"Graf","year":"1994","unstructured":"Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U (1994) Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 12:1443","journal-title":"J Clin Oncol"},{"key":"0552_CR9","unstructured":"Grubb A (1992) Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 38 [Suppl 1]:20"},{"key":"0552_CR10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1080\/080352598750031149","volume":"87","author":"Gustafsson","year":"1998","unstructured":"Gustafsson G, Kreuger A, Clausen N, Garwicz S, Kristinsson J, Lie SO, Moe PJ, Perkkio M, Yssing M, Saarinen-Pihkala UM (1998) Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Acta Paediatr 87:1151","journal-title":"Acta Paediatr"},{"key":"0552_CR11","first-page":"221","volume":"49","author":"Helin","year":"1998","unstructured":"Helin I, Axenram M, Grubb A (1998) Serum cystatin C as a determinant of glomerular filtration rate in children. Clin Nephrol 49:221","journal-title":"Clin Nephrol"},{"key":"0552_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/00365510050185056","volume":"60","author":"Hjorth","year":"2000","unstructured":"Hjorth L, Helin I, Grubb A (2000) Age-related reference limits for urine levels of albumin, orosomucoid, immunoglobulin G and protein HC in children. Scand J Clin Lab Invest 60:65","journal-title":"Scand J Clin Lab Invest"},{"key":"0552_CR13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1172\/JCI108308","volume":"57","author":"Jacobs","year":"1976","unstructured":"Jacobs SA, Stoller RG, Chabner BA, Johns DG (1976) 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest 57:534","journal-title":"J Clin Invest"},{"key":"0552_CR14","first-page":"651","volume":"61","author":"Jacobs","year":"1977","unstructured":"Jacobs SA, Stoller RG, Chabner BA, Johns DG (1977) Dose-dependent metabolism of methotrexate in man and rhesus monkeys. Cancer Treat Rep 61:651","journal-title":"Cancer Treat Rep"},{"key":"0552_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s002800050534","volume":"39","author":"Johnsson","year":"1996","unstructured":"Johnsson A, Hoglund P, Grubb A, Cavallin-Stahl E (1996) Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head\/neck or esophagus. Cancer Chemother Pharmacol 39:25","journal-title":"Cancer Chemother Pharmacol"},{"key":"0552_CR16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1055\/s-2008-1046623","volume":"206","author":"Lawrenz-Wolf","year":"1994","unstructured":"Lawrenz-Wolf B, Wolfrom C, Frickel C, Fengler R, Wehinger H, Henze G (1994) Severe renal impairment of methotrexate elimination after high dose therapy (in German). Klin Padiatr 206:319","journal-title":"Klin Padiatr"},{"key":"0552_CR17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/j.1875-9114.1995.tb04347.x","volume":"15","author":"Murry","year":"1995","unstructured":"Murry DJ, Synold TW, Pui CH, Rodman JH (1995) Renal function and methotrexate clearance in children with newly diagnosed leukemia. Pharmacotherapy 15:144","journal-title":"Pharmacotherapy"},{"key":"0552_CR18","first-page":"17","volume":"47","author":"Nilsson-Ehle","year":"1994","unstructured":"Nilsson-Ehle P, Grubb A (1994) New markers for the determination of GFR: iohexol clearance and cystatin C serum concentration. Kidney Int Suppl 47:17","journal-title":"Kidney Int Suppl"},{"key":"0552_CR19","first-page":"709","volume":"61","author":"Pinedo","year":"1977","unstructured":"Pinedo HM, Chabner BA (1977) Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity. Cancer Treat Rep 61:709","journal-title":"Cancer Treat Rep"},{"key":"0552_CR20","first-page":"445","volume":"37","author":"Pinedo","year":"1977","unstructured":"Pinedo HM, Zaharko DS, Bull J, Chabner BA (1977) The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion. Cancer Res 37:445","journal-title":"Cancer Res"},{"key":"0552_CR21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/adc.81.4.339","volume":"81","author":"Rees","year":"1999","unstructured":"Rees H, Hann IM, Chessells JM, Webb DK (1999) Are glomerular filtration rate estimations necessary before high dose methotrexate? Arch Dis Child 81:339","journal-title":"Arch Dis Child"},{"key":"0552_CR22","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.1994.12.8.1667","volume":"12","author":"Relling","year":"1994","unstructured":"Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE (1994) Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 12:1667","journal-title":"J Clin Oncol"},{"key":"0552_CR23","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0272-6386(86)80112-3","volume":"8","author":"Ries","year":"1986","unstructured":"Ries F, Klastersky J (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8:368","journal-title":"Am J Kidney Dis"},{"key":"0552_CR24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.1991.9.10.1766","volume":"9","author":"Saeter","year":"1991","unstructured":"Saeter G, Alvegard TA, Elomaa I, Stenwig AE, Holmstrom T, Solheim OP (1991) Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 9:1766","journal-title":"J Clin Oncol"},{"key":"0552_CR25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/BF00548590","volume":"19","author":"Sand","year":"1981","unstructured":"Sand TE, Jacobsen S (1981) Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 19:453","journal-title":"Eur J Clin Pharmacol"},{"key":"0552_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s002800050115","volume":"34","author":"Smeland","year":"1994","unstructured":"Smeland E, Bremnes RM, Andersen A, Jaeger R, Eide TJ, Huseby NE, Aarbakke J (1994) Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. Cancer Chemother Pharmacol 34:119","journal-title":"Cancer Chemother Pharmacol"},{"key":"0552_CR27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/00365519409088425","volume":"54","author":"Tencer","year":"1994","unstructured":"Tencer J, Thysell H, Andersson K, Grubb A (1994) Stability of albumin, protein HC, immunoglobulin G, kappa- and lambda-chain immunoreactivity, orosomucoid and alpha 1-antitrypsin in urine stored at various conditions. Scand J Clin Lab Invest 54:199","journal-title":"Scand J Clin Lab Invest"},{"key":"0552_CR28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3109\/00365519609088816","volume":"56","author":"Tencer","year":"1996","unstructured":"Tencer J, Thysell H, Grubb A (1996) Analysis of proteinuria: reference limits for urine excretion of albumin, protein HC, immunoglobulin G, kappa- and lambda-immunoreactivity, orosomucoid and alpha 1-antitrypsin. Scand J Clin Lab Invest 56:691","journal-title":"Scand J Clin Lab Invest"},{"key":"0552_CR29","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1200\/JCO.1993.11.5.827","volume":"11","author":"Wolfrom","year":"1993","unstructured":"Wolfrom C, Hartmann R, Fengler R, Bruhmuller S, Ingwersen A, Henze G (1993) Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol 11:827","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-002-0552-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-002-0552-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-002-0552-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T12:53:10Z","timestamp":1722171190000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-002-0552-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3,28]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["0552"],"URL":"https:\/\/doi.org\/10.1007\/s00280-002-0552-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3,28]]}}}